Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: A systematic review and meta-analysis

European Urology

Volumn 69, Issue 4, 2016, Pages 563-573

  Tucci, Marcello ^a   Bertaglia, Valentina ^a   Vignani, Francesca ^a   Buttigliero, Consuelo ^a   Fiori, Cristian ^a   Porpiglia, Francesco ^a   Scagliotti, Giorgio Vittorio ^a   Di Maio, Massimo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Androgen deprivation therapy; Chemotherapy; Docetaxel; Hormone sensitive prostate cancer; Meta analysis; Systematic review

Indexed keywords

ANTIANDROGEN; DOCETAXEL; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAXOID;

ALOPECIA; ANDROGEN DEPRIVATION THERAPY; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; HORMONE SENSITIVE METASTATIC PROSTATE CANCER; HUMAN; INCIDENCE; MALE; MEDICATION COMPLIANCE; META ANALYSIS; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; AGED; CHI SQUARE DISTRIBUTION; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; NEOPLASMS, HORMONE-DEPENDENT; ODDS RATIO; PATHOLOGY; PROSTATIC NEOPLASMS; RISK FACTOR; TIME FACTOR; TUMOR VOLUME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; ODDS RATIO; PROSTATIC NEOPLASMS; RISK FACTORS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84959261225     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.09.013     Document Type: Review

References (37)

1. L.A. Torre, F. Bray, R.L. Siegel, and et al. Global Cancer Statistics, 2012 CA Cancer J Clin 65 2015 87 108
2. S.J. Freedland, E.B. Humphreys, L.A. Mangold, and et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality J Clin Oncol 25 2007 1765 1771
3. R. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J Clin 65 2015 5 29
4. C. Huggins, R.E. Stevens, and C.V. Hodges Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland Arch Surg 43 1941 209 223
5. B.A. Hellerstedt, and K.J. Pienta The current state of hormonal therapy for prostate cancer CA Cancer J Clin 52 2002 154 179
6. I.F. Tannock, R. de Wit, W.R. Berry, and et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
7. D.P. Petrylak, C.M. Tangen, M.H. Hussain, and et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
8. J. de Bono, C. Logothetis, A. Molina, and et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
9. H.I. Scher, K. Fizazi, F. Saad, and et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
10. P.W. Kantoff, C.S. Higano, N.D. Shore, and et al. Sipuleucel T immunotherapy for castrate-resistant prostate cancer N Engl J Med 363 2010 411 422
11. J.S. de Bono, S. Oudard, M. Ozguroglu, and et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
12. C. Parker, S. Nilsson, D. Heinrich, and et al. Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213 223
13. H.I. Scher, and C.K. Sawyers Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis J Clin Oncol 23 2005 8253 8261
14. P.S. Nelson Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signalling in prostate cancer J Clin Oncol 30 2012 644 646
15. E.A. Mostaghel, B.T. Marck, S.R. Plymate, and et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants Clin Cancer Res 17 2011 5913 5925
16. M.A. Fenton, T.D. Shuster, Feting Am, and et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer Clin Cancer Res 3 1997 1383 1388
17. E.S. Antonarakis, C. Lu, H. Wang, and et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer N Engl J Med 371 2014 1028 1038
18. M. Stanbrough, G.J. Bubley, K. Ross, and et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 66 2006 2815 2825
19. M. Ahmed, and L.C. Li Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective Int J Urol 20 2013 362 371
20. R.E. Millikan, S. Wen, L.C. Pagliaro, and et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer J Clin Oncol 26 2008 5936 5942
21. J. Wang, S. Halford, A. Rigg, R. Roylance, M. Lynch, and J. Waxman Adjuvant mitoxantrone chemotherapy in advanced prostate cancer BJU Int 86 2000 675 680
22. G. Gravis, K. Fizazi, F. Joly, and et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Lancet Oncol 14 2013 149 158
23. C.J. Sweeney, Y.H. Chen, M. Carducci, and et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer N Engl J Med 373 2015 737 746
24. N.D. James, M.R. Sydes, M.D. Mason, and et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first overall survival results from STAMPEDE (NCT00268476) [abstract 5001] J Clin Oncol 33 Suppl 2015
25. K. Fizazi, L. Faivre, F. Lesaunier, and et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial Lancet Oncol 16 2015 787 794
26. H.M. Sandler, C. Hu, S.A. Rosenthal, and et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521) [abstract LBA5002] J Clin Oncol 33 Suppl 2015
27. G. Gravis, J.-M. Boher, F. Joly, and et al. Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): long-term analysis of the GETUG-AFU 15 phase III trial [abstract 140] J Clin Oncol 33 Suppl 7 2015
28. P. Piedbois, and M. Buyse Meta-analyses based on abstracted data: a step in the right direction, but only a first step J Clin Oncol 22 2004 3839 3841
29. G.S. Prins, L. Birch, and G.L. Greene Androgen receptor localization in different cell types of the adult rat prostate Endocrinology 129 1991 3187 3199
30. T. Karantanos, P.G. Corn, and T.C. Thompson Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches Oncogene 32 2013 5501 5511
31. M.S. Darshan, M.S. Loftus, M. Thadani-Mulero, and et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer Cancer Res 71 2011 6019 6029
32. M. Thadani-Mulero, D.M. Nanus, and P. Giannakakou Androgen receptor on the move: boarding the microtubule expressway to the nucleus Cancer Res 72 2012 4611 4615
33. K.J. Pienta Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer Semin Oncol 28 Suppl 15 2001 3 7
34. M.A. Eisenberger, B.A. Blumenstein, E.D. Crawford, and et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer N Engl J Med 339 1998 1036 1042
35. E.D. Crawford, M.A. Eisenberger, D.G. McLeod, and et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N Engl J Med 321 1989 419 424
36. M. Hussain, C.M. Tangen, D.L. Berry, and et al. Intermittent versus continuous androgen deprivation in prostate cancer N Engl J Med 368 2013 1314 1325
37. N.D. James, M.R. Spears, N.W. Clarke, and et al. Survival with newly diagnosed metastatic prostate cancer in the "docetaxel era": data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019) Eur Urol 67 2015 1028 1038